Pharmacy spending is once again the fastest growing component of employer health plans. Specialty drugs now account for more than half of total pharmacy spend, and GLP 1 medications for diabetes and weight management are reshaping budgets. Employers are feeling the pressure: rising premiums, unpredictable claims, and employee expectations for access to high cost therapies.
After several years of experimentation, many employers are tightening hybrid schedules or requiring more in-office days. This “return-to-office reset” is reshaping benefits strategies as organizations look for ways to support commuting employees, improve onsite experience, and maintain flexibility. What began as a workplace policy shift is now driving a broader rethinking of how benefits can reinforce culture, productivity, and retention.
A troubling new study reveals that the majority of employees are not using all of their paid time off (PTO), costing them and their employers.
As mid-year approaches, employers sponsoring benefit plans should begin preparing for upcoming Form 5500 filing obligations. For many calendar-year plans, Form 5500 filings are due by July 31, making June an ideal time to confirm whether filing requirements apply and ensure needed information is being gathered.
Self funding is no longer just for large employers. In 2026, small and mid sized businesses are embracing level funded and partially self funded plans at record rates. Rising premiums, greater access to stop loss coverage, and improved data analytics are making self funding a viable option for groups as small as 25–50 employees.
Chronic conditions have long been the primary driver of employer healthcare spending, but 2026 marks a turning point in how organizations are approaching prevention, treatment, and long-term management. With GLP-1 medications dominating headlines — and budgets — employers are urgently exploring complementary or alternative strategies that can improve outcomes without unsustainable cost growth. The result is a new wave of digital therapeutics, metabolic health programs, and integrated care models that promise a more balanced approach to chronic disease management.
Each year, group health plans must report detailed prescription drug and healthcare spending data to the Centers for Medicare & Medicaid Services (CMS). This reporting—commonly referred to as RxDC reporting—is due by June 1 and applies to most employer-sponsored group health plans that offer prescription drug coverage.
Virtual care is entering a new phase in 2026, with employers seeing rapid growth in Telehealth 2.0 — a more integrated, data driven model that blends virtual visits, remote monitoring, and AI supported clinical decision tools. Analysts describe this shift as a move from “occasional convenience” to a core component of everyday care delivery.
The Affordable Care Act established the Patient-Centered Outcomes Research Institute (PCORI) to support research evaluating the effectiveness of medical treatments and healthcare delivery. To help fund this work, certain employer-sponsored health plans must pay an annual PCORI fee.
Mental health parity has been a compliance requirement for more than a decade, but 2026 marks a decisive shift in how aggressively federal agencies are enforcing it. Employers who once relied on carriers to “handle parity in the background” are now discovering that regulators expect detailed documentation, transparent processes, and clear evidence that mental health and substance use disorder (MH/SUD) benefits are administered on equal terms with medical and surgical benefits.
